Patent details
300817
Product Name:
humaan alfa1-proteïnaseremmer
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300817
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2295126
Status:
Refused Art. 10 of the EC Regulations
Application number:
300817
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/15/1006/001
Marketing Authorization Type:
EEA
Marketing Authorization Date:
25/08/2015
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
06/06/2016
First Marketing Authorization date:
25/08/2015
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
09/06/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
22/02/2022
Applicant/holder
From:
09/06/2016
Name:
CSL Behring LLC
Address:
1020 First Avenue, KING OF PRUSSIA, PA 19406, United States of America (US)
Agent
Name:
ir. F.A. Geurts c.s.
From:
09/06/2016
Address:
Octrooibureau Vriesendorp & Gaade B.V.
Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
08/22
Publication date:
23/02/2022
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
23/16
Publication date:
10/06/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
22/02/2022
Outgoing Correspondence
Decision refusal
2
PDF
/6/5/7/3/6/0800063756/docs/300817_4_463945l527a.pdf
16/12/2021
Outgoing Correspondence
Letter to applicant
1
PDF
/6/5/7/3/6/0800063756/docs/300817_2_451630l173.pdf
03/01/2017
Outgoing Correspondence
Outgoing Letter
1
PDF
/6/5/7/3/6/0800063756/docs/300817_6_outgoingcorrespondence20170104100518662.pdf
19/12/2016
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/6/5/7/3/6/0800063756/docs/300817_10_incomingcorrespondencepaper20161221033851524.pdf
15/06/2016
Outgoing Correspondence
Outgoing Letter
1
PDF
/6/5/7/3/6/0800063756/docs/300817_8_61712l174.pdf
06/06/2016
SPC Documents
Annex SPC
2
PDF
/6/5/7/3/6/0800063756/docs/300817_0_supplprotectioncertificate20200415101414741.pdf
06/06/2016
SPC Documents
Accompanying letter SPC
1
PDF
/6/5/7/3/6/0800063756/docs/300817_1_supplprotectioncertificate20210406013606778.pdf
06/06/2016
SPC Documents
Annex SPC
1
PDF
/6/5/7/3/6/0800063756/docs/300817_3_supplprotectioncertificate20200415101206993.pdf
06/06/2016
SPC Documents
Summary of the characteristics of the product
11
PDF
/6/5/7/3/6/0800063756/docs/300817_5_supplprotectioncertificate20200415101028536.pdf
06/06/2016
SPC Documents
Marketing Authorization SPC
3
PDF
/6/5/7/3/6/0800063756/docs/300817_7_supplprotectioncertificate20160609043350247.pdf
06/06/2016
Application Form
First filed application form
3
PDF
/6/5/7/3/6/0800063756/docs/300817_9_applicationform20160609043349977.pdf